DURHAM, N.C. and BEIJING, Dec. 12, 2021 /PRNewswire/ — Brii Biosciences Limited (stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens, today announced new in vitro pseudoviris neutralization data demonstrating that its amubarvimab/romlusevimab combination therapy (previously